Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Change in Accured Expenses (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Change in Accured Expenses for 15 consecutive years, with -$741000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 11.93% to -$741000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $508000.0, a 239.94% increase, with the full-year FY2024 number at -$195000.0, up 82.7% from a year prior.
  • Change in Accured Expenses was -$741000.0 for Q3 2025 at NovaBay Pharmaceuticals, up from -$779000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q1 2025 to a low of -$1.5 million in Q3 2023.
  • A 5-year average of -$33684.2 and a median of $78000.0 in 2022 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 948.15% in 2025; the steepest drop was 3016.0% in 2025.
  • NovaBay Pharmaceuticals' Change in Accured Expenses stood at -$425000.0 in 2021, then skyrocketed by 226.82% to $539000.0 in 2022, then plummeted by 69.94% to $162000.0 in 2023, then skyrocketed by 103.7% to $330000.0 in 2024, then plummeted by 324.55% to -$741000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Change in Accured Expenses are -$741000.0 (Q3 2025), -$779000.0 (Q2 2025), and $1.7 million (Q1 2025).